Literature DB >> 21948893

Family history of dementia predicts worse neuropsychological functioning among HIV-infected persons.

David J Moore1, Miguel Arce, Suzanne Moseley, J Allen McCutchan, Jennifer Marquie-Beck, Donald R Franklin, Florin Vaida, Cristian L Achim, Justin McArthur, Susan Morgello, David M Simpson, Benjamin B Gelman, Ann C Collier, Christina M Marra, David B Clifford, Robert K Heaton, Igor Grant.   

Abstract

HIV-negative individuals with a family history of dementia (FHD) are more likely to develop dementia than those without FHD. Whether FHD increases risk for neuropsychological (NP) impairment in HIV+ persons is unknown. As part of a multisite study into HIV-associated neurocognitive disorders (HAND), the authors captured FHD with a free-response, self-report question, and assessed NP performance with a comprehensive battery of tests. The authors examined HIV+ persons with (N=190) and without (N=916) self-reported FHD. Despite the fact that the FHD group had factors typically associated with better NP performance (e.g., higher CD4 counts and estimated verbal IQ), persons with FHD had significantly worse NP ability than those without FHD as measured by a Global Deficit Score. Thus, FHD appears to be a risk factor for HAND; the mechanism(s) underlying how FHD contributes to NP impairment among HIV+ persons warrants study.

Entities:  

Mesh:

Year:  2011        PMID: 21948893      PMCID: PMC3279193          DOI: 10.1176/jnp.23.3.jnp316

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  55 in total

Review 1.  Advances in the treatment of HIV dementia.

Authors:  N C Sacktor
Journal:  AIDS Read       Date:  1999 Jan-Feb

2.  Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection.

Authors:  Catherine L Carey; Steven Paul Woods; Raul Gonzalez; Emily Conover; Thomas D Marcotte; Igor Grant; Robert K Heaton
Journal:  J Clin Exp Neuropsychol       Date:  2004-05       Impact factor: 2.475

3.  Risk factors for Alzheimer's disease: overview of the EURODEM collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group.

Authors:  C M van Duijn; T Stijnen; A Hofman
Journal:  Int J Epidemiol       Date:  1991       Impact factor: 7.196

4.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

Authors:  E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Science       Date:  1993-08-13       Impact factor: 47.728

5.  Effect of aging on brain metabolism in antiretroviral-naive HIV patients.

Authors:  Thomas Ernst; Linda Chang
Journal:  AIDS       Date:  2004-01-01       Impact factor: 4.177

Review 6.  Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms.

Authors:  Victor G Valcour; Cecilia M Shikuma; Michael R Watters; Ned C Sacktor
Journal:  AIDS       Date:  2004-01-01       Impact factor: 4.177

7.  Prevalence of cognitive disorders differs as a function of age in HIV virus infection.

Authors:  James T Becker; Oscar L Lopez; Mary Amanda Dew; Howard J Aizenstein
Journal:  AIDS       Date:  2004-01-01       Impact factor: 4.177

8.  Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV.

Authors:  Steven Paul Woods; Julie D Rippeth; Alan B Frol; Joel K Levy; Elizabeth Ryan; Vicki M Soukup; Charles H Hinkin; Deborah Lazzaretto; Mariana Cherner; Thomas D Marcotte; Benjamin B Gelman; Susan Morgello; Elyse J Singer; Igor Grant; Robert K Heaton
Journal:  J Clin Exp Neuropsychol       Date:  2004-09       Impact factor: 2.475

9.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

10.  Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort.

Authors:  V Valcour; C Shikuma; B Shiramizu; M Watters; P Poff; O Selnes; P Holck; J Grove; N Sacktor
Journal:  Neurology       Date:  2004-09-14       Impact factor: 9.910

View more
  6 in total

1.  Planning deficits in HIV-associated neurocognitive disorders: component processes, cognitive correlates, and implications for everyday functioning.

Authors:  Jordan E Cattie; Katie Doyle; Erica Weber; Igor Grant; Steven Paul Woods
Journal:  J Clin Exp Neuropsychol       Date:  2012-06-25       Impact factor: 2.475

2.  The current understanding of overlap between characteristics of HIV-associated neurocognitive disorders and Alzheimer's disease.

Authors:  Leah H Rubin; Erin E Sundermann; David J Moore
Journal:  J Neurovirol       Date:  2019-01-22       Impact factor: 2.643

3.  Major depressive disorder, cognitive symptoms, and neuropsychological performance among ethnically diverse HIV+ men and women.

Authors:  Robert P Fellows; Desiree A Byrd; Susan Morgello
Journal:  J Int Neuropsychol Soc       Date:  2013-01-04       Impact factor: 2.892

4.  Prepulse inhibition in HIV-associated neurocognitive disorders.

Authors:  Arpi Minassian; Brook L Henry; Steven Paul Woods; Florin Vaida; Igor Grant; Mark A Geyer; William Perry
Journal:  J Int Neuropsychol Soc       Date:  2013-04-03       Impact factor: 2.892

5.  Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia.

Authors:  Pariya L Fazeli; David J Moore; Donald R Franklin; Anya Umlauf; Robert K Heaton; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Ned C Sacktor; Susan Morgello; David M Simpson; John A McCutchan; Igor Grant; Scott L Letendre
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

Review 6.  Opiate drug use and the pathophysiology of neuroAIDS.

Authors:  Kurt F Hauser; Sylvia Fitting; Seth M Dever; Elizabeth M Podhaizer; Pamela E Knapp
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.